Małgorzata Dudzic

Dr. Małgorzata Dudzic

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2025 in Toxins
Verified
Journal Article
Open access
PDF file
MDMałgorzata Dudzic
Małgorzata Dudzic
APAnna Pieczyńska
Anna Pieczyńska
ADArtur Drużdż
Artur Drużdż
ARAnna Rajewska
Anna Rajewska
Katarzyna HojanKatarzyna Hojan
Katarzyna Hojan
The efficacy of botulinum toxin A (BoNT) in alleviating motor symptoms of cervical dystonia (CD) has been well established, and it is the treatment of choice in this disease. Lately, the effect of BoNT on non-motor symptoms (NMS) such as cognitive function, depression, anxiety, pain, and sleep disturbance has been observed in patients with CD. A comprehensive clinical and functional assessment of motor (dystonia severity, gait) and non-motor symptoms (cognitive functions, depression, anxiety, sleep, and pain) has been performed in a total of 34 adult patients with cervical dystonia before and after BoNT treatment. Results have also been compared to a control group. Significant improvements in the scales assessing dystonia severity have been observed, which is in line with previous studies on the effect of BoNT on motor symptoms in dystonia. Interestingly, the results also clearly indicate that BoNT has a positive effect on NMS. Among the studied non-motor domains, depression and cognitive functions improved the most after the treatment procedure. The study highlights the potential of BoNT to positively influence non-motor symptoms in patients with cervical dystonia, although its effect on various NMS is not equal.

14 February 2025 in Neurologia i Neurochirurgia Polska
Verified
Journal Article
Closed access
MDMałgorzata Dudzic
Małgorzata Dudzic
APAnna Pieczyńska
Anna Pieczyńska
ADArtur Drużdż
Artur Drużdż
KHKatarzyna Hojan
Katarzyna Hojan
The effect of botulinum toxin A (BoNTA) on non-motor symptoms (NMS) in patients with cervical dystonia remains an area of significant clinical interest, given the profound impact of these symptoms on patients' quality of life. While the therapeutic efficacy of BoNTA in alleviating motor symptoms of cervical dystonia is well established, its impact on NMS such as depression, anxiety disorder, and sleep disturbance requires further investigation. This systematic review synthesizes the latest evidence on the effects of BoNTA on these selected non-motor symptoms. A comprehensive search of the PubMed, Web of Science, and Scopus databases identified 266 articles, of which eight studies met our strict inclusion criteria. Pre- and post-intervention changes in depression, anxiety, and sleep disturbance were assessed in a total of 280 adult patients with cervical dystonia treated with BoNTA. The results indicate that BoNTA has a positive effect on depressive symptoms, with most studies showing a statistically significant improvement after treatment. Similarly, studies are reporting significant reductions in anxiety scores following BoNTA treatment. However, the effects of this treatment method on sleep disturbances were less conclusive, with none of the reviewed studies showing significant improvements in sleep quality or daytime sleepiness. The results highlight the potential of BoNTA to positively influence non-motor symptoms, particularly depression and anxiety, in patients with cervical dystonia, although its effects on sleep remain unclear. These findings underscore the need for further research to fully understand the mechanisms underlying the non-motor effects of BoNTA and to develop comprehensive treatment strategies.

30 December 2025 in Toxins
Verified
Journal Article
Open access
PDF file
ADArtur Drużdż
Artur Drużdż
ELEdyta Leśniewska-Furs
Edyta Leśniewska-Furs
MDMałgorzata Dudzic
Małgorzata Dudzic
ASAnna Sowinska
Anna Sowinska
SJSzymon Jurga
Szymon Jurga
Wolfgang JostWolfgang Jost
Wolfgang Jost
While distinguishing between collis and caput patterns in cervical dystonia (CD) has clear clinical and therapeutic relevance, the effects of botulinum toxin type A (BoNT-A) on segmental spinal excitability and inhibitory function in caput-pattern CD have not been previously investigated. This study aimed to advance understanding of the effects of BoNT-A and its broader neurophysiological impact in cervical dystonia, particularly in the caput subtype. The study utilised non-invasive neurophysiological methods to assess F-wave and cutaneous silent period (CSP or CuSP) parameters in 21 CD patients with caput motor patterns at waning and peak response phases of BoNT-A therapy. Significant prolongation of Fmin latency, increased F–M interlatency, reduced F-wave amplitude, and a marked increase in CSP duration and onset latencies were observed following BoNT-A administration, indicating that BoNT-A not only reduces spinal motoneuron excitability and strengthens spinal inhibitory processes, but also highlights its capacity to modulate central sensorimotor pathways beyond local chemodenervation. Together, the observed changes in CSP support its use as a potential biomarker for nervous system effects of BoNT-A in dystonia; however, further validation in controlled studies is warranted.

23 October 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
IBIlona Bar-Letkiewicz
Ilona Bar-Letkiewicz
APAnna Pieczyńska
Anna Pieczyńska
MDMałgorzata Dudzic
Małgorzata Dudzic
MSMichał Szkudlarek
Michał Szkudlarek
KAKrystyna Adamska
Krystyna Adamska
Katarzyna HojanKatarzyna Hojan
Katarzyna Hojan
Despite technological progress, glioblastoma (GBM) continues to confer dismal prognoses. Modern neuroimaging methods are assuming an ever greater role in diagnosing and monitoring brain tumors. This review shows current neuroimaging approaches and systemic therapeutic strategies for glioblastoma, with a focus on emerging and innovative treatments. Advances in multiparametric magnetic resonance imaging—MRI (diffusion, perfusion, and spectroscopy) and novel positron emission tomography (PET) tracers, complemented by radiomics and artificial intelligence (AI), now refine tumor delineation, differentiate progression from treatment effects, and may help predict treatment responses. Maximal safe resection followed by chemoradiotherapy with temozolomide remains the standard, with the greatest benefit seen in O6-methylguanine DNA methyltransferase (MGMT) promoter-methylated tumors. Bevacizumab and other targeted modalities offer mainly progression-free, not overall survival, gains. Immune checkpoint inhibitors (e.g., nivolumab) have not improved survival in unselected GBM, while early multi-antigen CAR-T (chimeric antigen receptor T-cell) strategies show preliminary bioactivity without established durability. While actionable alterations (NTRK fusions and BRAF V600E) justify selective targeted therapy trials, their definitive benefit in classical GBM is unproven. Future priorities include harmonized imaging molecular integration, AI-driven prognostic modeling, novel PET tracers, and strategies to breach or transiently open the blood–brain barrier to enhance drug delivery. Convergence of these domains may convert diagnostic precision into improved patient outcomes.

2 July 2026 in Molecules
Verified
Journal Article
Open access
PDF file
AKAleksandra Kinga Kwiecień
Aleksandra Kinga Kwiecień
MDMałgorzata Dudzic
Małgorzata Dudzic
ALAndrzej Lemański
Andrzej Lemański
JKJustin M Kalka
Justin M Kalka
ADArtur Drużdż
Artur Drużdż
BSBartosz Sokół
Bartosz Sokół
Idiopathic normal pressure hydrocephalus (iNPH) is a potentially reversible neurological disorder characterized by gait disturbance, cognitive impairment, and urinary incontinence; however, its diagnosis and prediction of shunt responsiveness remain challenging. This systematic review aimed to synthesize current evidence on cerebrospinal fluid (CSF) proteomic biomarkers in iNPH and to identify molecular patterns with diagnostic and prognostic relevance. A PRISMA-guided search of PubMed, Web of Science, and Google Scholar identified 14 eligible studies comprising 1171 iNPH patients. Proteomic analyses revealed substantial heterogeneity in study design and detected proteins; however, consistent patterns emerged. iNPH is associated with upregulation of inflammatory and extracellular matrix-related proteins and relative downregulation of synaptic and neuronal markers. Neurodegenerative proteins, including amyloid-β, tau, and neurofilament light chain, demonstrated value in differentiating iNPH from comorbid neurodegenerative diseases and in predicting response to ventriculoperitoneal shunting (VPS). These findings support a multifactorial model of iNPH involving impaired glymphatic clearance, neuroinflammation, blood–brain barrier dysfunction, and mechanical axonal stress. Multidimensional biomarker profiles, rather than single proteins, appear to provide the greatest clinical utility, highlighting the need for standardized proteomic panels and integrative predictive models. However, given the substantial heterogeneity of the included studies and the predominantly exploratory nature of current proteomic evidence, the identified proteins should be interpreted as candidate biomarkers rather than clinically validated diagnostic or prognostic tools. Multidimensional biomarker profiles appear biologically plausible and may offer greater explanatory value than single proteins, but their clinical utility requires validation in standardized prospective cohorts. The authors therefore propose a conceptual iNPH proteomic “Vulnerability Model” integrating CSF biomarkers to reflect the balance between reversible and irreversible pathology; this is currently a hypothetical model that requires rigorous statistical and clinical validation through large-scale prospective cohort studies before it can fulfill its potential for improving patient stratification and prediction of postoperative outcomes.

4 March 2026 in Neurologia i Neurochirurgia Polska
Verified
Journal Article
Open access
PDF file
MDMałgorzata Dudzic
Małgorzata Dudzic
APAnna Pieczyńska
Anna Pieczyńska
ADArtur Drużdż
Artur Drużdż
ARAnna Rajewska
Anna Rajewska
PDPiotr Dudzic
Piotr Dudzic
KHKatarzyna Hojan
Katarzyna Hojan
Aim of the study. To investigate subtle cognitive dysfunction in patients with cervical dystonia (CD) as a potential independent non-motor feature of the disease or as a consequence of interactions between motor and other non-motor symptoms (NMS). Clinical rationale for the study. Cognitive impairment represents one of the most common non-motor symptoms in patients with cervical dystonia. However, the interrelations between cognitive dysfunction, motor symptoms, and other non-motor symptoms remain insufficiently explored. Material and methods. Patients with CD (n = 34) underwent comprehensive assessment at baseline and 4–6 weeks after botulinum toxin (BoNT) treatment. Clinical and sociodemographic variables, as well as motor and non-motor symptoms of dystonia were assessed. Matched controls (n = 33) underwent a single assessment. Cognitive function, depressive and anxiety symptoms, and sleep disturbances were assessed by a neuropsychologist in both groups. Results. At baseline, 52.9% of patients with CD scored below the Montreal Cognitive Assessment (MoCA) cut-off for cognitive impairment, compared with 3.0% of healthy controls. Patients also showed higher rates of depressive symptoms, anxiety, and sleep disturbances. Cognitive performance was significantly lower in the CD group across multiple domains [executive functions, visuospatial abilities, language, memory, and attention (p < 0.05)]. Following botulinum toxin treatment, significant improvements were observed in overall MoCA scores and in specific domains of executive function, visuospatial abilities, language, and memory (p < 0.05). No correlation was found between overall dystonia severity and cognitive performance, although executive function correlated with motor symptom severity at baseline (R = –0.41, p = 0.017). In the multivariate model, sleep disturbances were identified as the strongest negative predictor of cognitive function (β = –0.40, p = 0.006), while higher education showed a protective effect. Other variables, including depression, anxiety, age, disease duration, and dystonia severity, were not significant predictors. Conclusions and clinical implications. The study explores cognitive impairment in cervical dystonia in relation to motor severity and non-motor domains, with the multivariable model suggesting a potential role of sleep disturbances. The findings do not allow a definitive distinction between cognitive impairment as a core feature of dystonia or a secondary effect related to non-motor symptoms, but they indicate complex and interdependent mechanisms. Keywords: cervical dystonia cognitive impairment non-motor symptoms depression anxiety sleep disturbances botulinum toxin